

Demographics, Orders, Results and Clindoc

Parameters: From Date: 2014/01/01 To Date: 2016/03/17
MRN: 02295048
Chart Group: Oncology
Include Documentation: Yes Include Results: Yes
Include Orders: Yes

Report Definition: This report is part 1 of 3 that details patient information per chart group. It consists of patient demographics, orders, results and clindoc.

Patient Name: REIGERT, LORI A **MRN:** 02295048 **Age (DOB):** 40y(16-Dec-1975)

Documents

07-Jan-2016 13:45 **Clinic Note - Heme Onc- New Visit, melanoma** **Koon, Henry B (MD)**

Patient Visit Information:

Visit Type: New Visit, melanoma

History of Present Illness:

Chief Complaint: Melanoma initial consultation

Interval History:

This is a 40 year old female with newly diagnosed malignant melanoma. She presented with metastatic disease to the right lung, malignant pleural effusion, primary site unknown. Approximately 3 months ago she began to have right sided shoulder and posterior upper quadrant pain which was felt to be due to a muscle strain. She subsequently had a fall and experienced ongoing disproportionate pain for the trauma. She went to the ER on December 19 with shooting pain in her right side. MRI was completed which found a lung lesion, per patient this was initially thought to be a hematoma. Further evaluation and work up lead to diagnosis of metastatic melanoma. She had a VATs / pleurodesis in December for biopsy and symptoms control. She denies any fever, chills, nausea. She has reports no vomiting, diarrhea. Her appetite is diminished and her weight is down. She is fatigued and her pain is not completely under control. She is constipated. No rash or pruritis.

Review of Systems:

- System Review All other systems have been reviewed and are negative for complaint.

Allergies and Intolerances:

Allergies:

penicillin Drug Hives/Urticaria Active

Outpatient Medication Profile:

* Patient Currently Takes Medications as of 07-Jan-2016 13:13 documented in Prescription Writer

docusate sodium 100 mg oral capsule, 1 cap(s) orally 2 times a day, As Needed
MiraLax oral powder for reconstitution, 17 gram(s) orally once a day
oxyCODONE 15 mg oral tablet, 1 tab(s) orally every 3 hours, As Needed
OxyCONTIN 10 mg oral tablet, extended release, 2 tab(s) orally every 12 hours
pantoprazole 40 mg oral delayed release tablet, 1 tab(s) orally once a day
Prenatal 1 Plus 1 oral tablet, 1 tab(s) orally once a day
promethazine 25 mg oral tablet, 1 tab(s) orally every 4 hours, As Needed
scopolamine 1.5 mg transdermal film, extended release, 1 patch transdermal every 72 hours
Tylenol 500 mg oral tablet, 2 tab(s) orally every 6 hours, As Needed
Valtrex 500 mg oral tablet, 1 tab(s) orally once a day
Xanax 0.25 mg oral tablet, 1 tab(s) orally 3 times a day, As Needed

Complete Chart Review Part 1 of 3 Demographics, Orders, Results and Clindoc

Parameters: From Date: 2014/01/01 To Date: 2016/03/17
MRN: 02295048
Chart Group: Oncology
Include Documentation: Yes Include Results: Yes
Include Orders: Yes

Report Definition: This report is part 1 of 3 that details patient information per chart group. It consists of patient demographics, orders, results and clindoc.

Patient Name: REIGERT, LORI A	MRN: 02295048	Age (DOB): 40y(16-Dec-1975)
--------------------------------------	----------------------	------------------------------------

senna oral tablet 2 tab(s) orally once a day
nystatin 100,000 units/mL oral suspension 5 milliliter(s) orally 4 times a day. As Needed

Medical History:

Pleural effusion Status: Active
Malignant melanoma Status: Active

Family History: No Family History items are recorded in the problem list.

Social History:

Smoking Status: never smoker

Tobacco Use: denies

Alcohol Use: occasionally

Drug Use: denies

Additional History:

Sales and Marketing Anheuser Busch. Lived in Columbus for 16 year before returning to Ohio this year (not related to illness).

Recently engaged.

Performance:

ECOG Performance Status: 1- Restricted from physically strenuous work

Vitals and Measurements:

Vitals: Temp: 36.8 HR: 99 RR: 16 BP: 139/81 SPO2%: NA

Measurements: HT(cm): 167.9 WT(kg): 63.8 BSA: 1.72 BMI: 22.6

Physical Exam:

Constitutional: Well developed, awake/alert/oriented x3, no distress, alert and cooperative

Eyes: PERRL, EOMI, clear sclera

ENMT: mucous membranes moist, no apparent injury, no lesions seen

Head/Neck: Neck supple, no apparent injury, thyroid without mass or tenderness, No JVD, trachea midline, no bruits

Respiratory/Thorax: Patent airways, diminished BS R posterior field, normal breath sounds with good chest expansion, thorax symmetric

Cardiovascular: Regular, rate and rhythm, no murmurs, 2+ equal pulses of the extremities, normal S1 and S2

Complete Chart Review Part 1 of 3 Demographics, Orders, Results and Clindoc

Parameters: From Date: 2014/01/01 To Date: 2016/03/17
 MRN: 02295048
 Chart Group: Oncology
 Include Documentation: Yes Include Results: Yes
 Include Orders: Yes

Report Definition: This report is part 1 of 3 that details patient information per chart group. It consists of patient demographics, orders, results and clindoc.

Patient Name: REIGERT, LORI A	MRN: 02295048	Age (DOB): 40y(16-Dec-1975)
--------------------------------------	----------------------	------------------------------------

Documents

07-Jan-2016 13:45	Clinic Note - Heme Onc- New Visit , melanoma	Koon, Henry B (MD)
--------------------------	---	---------------------------

Gastrointestinal: Nondistended, soft, non-tender, no rebound tenderness or guarding, no masses palpable, no organomegaly, +BS, no bruits

Musculoskeletal: ROM intact, no joint swelling, normal strength

Extremities: normal extremities, no cyanosis edema, contusions or wounds, no clubbing

Neurological: alert and oriented x3, intact senses, motor, response and reflexes, normal strength

Lymphatic: No significant lymphadenopathy

Psychological: Appropriate mood and behavior

Skin: Warm and dry, no lesions, no rashes

Assessment, Plan and Orders:

Assessment:

Patient with Stage IV melanoma She has had some moles removed and we will review that path as well as lung biopsy Will push routine bowel regimen and increase oxycontin. Will check path for 3 gene mutation panel and have her follow-up in 1 week for treatment with ipilimumab nivolumab. We reviewed side effects and potential benefits. If pain persists will have her see Onc supportive care.

Note Recipients: Donca, Mihaela, MD - 4405160492
 Van Heeckeren, Willem, MD

Electronic Signatures:

Koon, Henry B (MD) (Signed 07-Feb-2016 17:41)

Authored: Patient Visit Information, History of Present Illness, Review of Systems, Allergies and Outpatient Medication Profile, Problem List, Social History, Performance Assessments, Vitals and Measurements, Physical Exam, Assessment, Plan and Orders, To Send Document via Auto Fax

Last Updated: 07-Feb-2016 17:41 by Koon, Henry B (MD)

[Clinic Note - Heme Onc- New Visit , melanoma] -- End of Document